Literature DB >> 25903134

Factor VIII Interacts with the Endocytic Receptor Low-density Lipoprotein Receptor-related Protein 1 via an Extended Surface Comprising "Hot-Spot" Lysine Residues.

Maartje van den Biggelaar1, Jesper J Madsen2, Johan H Faber2, Marleen G Zuurveld3, Carmen van der Zwaan3, Ole H Olsen2, Henning R Stennicke2, Koen Mertens4, Alexander B Meijer4.   

Abstract

Lysine residues are implicated in driving the ligand binding to the LDL receptor family. However, it has remained unclear how specificity is regulated. Using coagulation factor VIII as a model ligand, we now study the contribution of individual lysine residues in the interaction with the largest member of the LDL receptor family, low-density lipoprotein receptor-related protein (LRP1). Using hydrogen-deuterium exchange mass spectrometry (HDX-MS) and SPR interaction analysis on a library of lysine replacement variants as two independent approaches, we demonstrate that the interaction between factor VIII (FVIII) and LRP1 occurs over an extended surface containing multiple lysine residues. None of the individual lysine residues account completely for LRP1 binding, suggesting an additive binding model. Together with structural docking studies, our data suggest that FVIII interacts with LRP1 via an extended surface of multiple lysine residues that starts at the bottom of the C1 domain and winds around the FVIII molecule.
© 2015 by The American Society for Biochemistry and Molecular Biology, Inc.

Entities:  

Keywords:  coagulation factor; factor VIII (FVIII); hydrogen exchange mass spectrometry; hydrogen-deuterium exchange; low-density lipoprotein receptor-related protein 1; protein-protein interaction; receptor; surface plasmon resonance (SPR)

Mesh:

Substances:

Year:  2015        PMID: 25903134      PMCID: PMC4505400          DOI: 10.1074/jbc.M115.650911

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  50 in total

1.  Structure of an LDLR-RAP complex reveals a general mode for ligand recognition by lipoprotein receptors.

Authors:  Carl Fisher; Natalia Beglova; Stephen C Blacklow
Journal:  Mol Cell       Date:  2006-04-21       Impact factor: 17.970

2.  Scalable molecular dynamics with NAMD.

Authors:  James C Phillips; Rosemary Braun; Wei Wang; James Gumbart; Emad Tajkhorshid; Elizabeth Villa; Christophe Chipot; Robert D Skeel; Laxmikant Kalé; Klaus Schulten
Journal:  J Comput Chem       Date:  2005-12       Impact factor: 3.376

3.  RAP, a specialized chaperone, prevents ligand-induced ER retention and degradation of LDL receptor-related endocytic receptors.

Authors:  T E Willnow; A Rohlmann; J Horton; H Otani; J R Braun; R E Hammer; J Herz
Journal:  EMBO J       Date:  1996-06-03       Impact factor: 11.598

4.  Identification of residues in alpha-macroglobulins important for binding to the alpha2-macroglobulin receptor/Low density lipoprotein receptor-related protein.

Authors:  K L Nielsen; T L Holtet; M Etzerodt; S K Moestrup; J Gliemann; L Sottrup-Jensen; H C Thogersen
Journal:  J Biol Chem       Date:  1996-05-31       Impact factor: 5.157

5.  LDL-receptor structure. Calcium cages, acid baths and recycling receptors.

Authors:  M S Brown; J Herz; J L Goldstein
Journal:  Nature       Date:  1997-08-14       Impact factor: 49.962

6.  The light chain of factor VIII comprises a binding site for low density lipoprotein receptor-related protein.

Authors:  P J Lenting; J G Neels; B M van den Berg; P P Clijsters; D W Meijerman; H Pannekoek; J A van Mourik; K Mertens; A J van Zonneveld
Journal:  J Biol Chem       Date:  1999-08-20       Impact factor: 5.157

7.  Binding of urokinase-type plasminogen activator-plasminogen activator inhibitor-1 complex to the endocytosis receptors alpha2-macroglobulin receptor/low-density lipoprotein receptor-related protein and very-low-density lipoprotein receptor involves basic residues in the inhibitor.

Authors:  K W Rodenburg; L Kjoller; H H Petersen; P A Andreasen
Journal:  Biochem J       Date:  1998-01-01       Impact factor: 3.857

8.  Plasminogen activator inhibitor-1 contains a cryptic high affinity binding site for the low density lipoprotein receptor-related protein.

Authors:  S Stefansson; S Muhammad; X F Cheng; F D Battey; D K Strickland; D A Lawrence
Journal:  J Biol Chem       Date:  1998-03-13       Impact factor: 5.157

9.  Molecular basis of familial hypercholesterolaemia from structure of LDL receptor module.

Authors:  D Fass; S Blacklow; P S Kim; J M Berger
Journal:  Nature       Date:  1997-08-14       Impact factor: 49.962

10.  Selective mutations in cloned and expressed alpha-macroglobulin receptor binding fragment alter binding to either the alpha2-macroglobulin signaling receptor or the low density lipoprotein receptor-related protein/alpha2-macroglobulin receptor.

Authors:  G C Howard; Y Yamaguchi; U K Misra; G Gawdi; A Nelsen; D L DeCamp; S V Pizzo
Journal:  J Biol Chem       Date:  1996-06-14       Impact factor: 5.157

View more
  9 in total

1.  High Affinity Binding of the Receptor-associated Protein D1D2 Domains with the Low Density Lipoprotein Receptor-related Protein (LRP1) Involves Bivalent Complex Formation: CRITICAL ROLES OF LYSINES 60 AND 191.

Authors:  Joni M Prasad; Patricia A Young; Dudley K Strickland
Journal:  J Biol Chem       Date:  2016-07-11       Impact factor: 5.157

2.  Evidence That Factor VIII Forms a Bivalent Complex with the Low Density Lipoprotein (LDL) Receptor-related Protein 1 (LRP1): IDENTIFICATION OF CLUSTER IV ON LRP1 AS THE MAJOR BINDING SITE.

Authors:  Patricia A Young; Mary Migliorini; Dudley K Strickland
Journal:  J Biol Chem       Date:  2016-10-29       Impact factor: 5.157

3.  α1-Antitrypsin derived SP16 peptide demonstrates efficacy in rodent models of acute and neuropathic pain.

Authors:  Zixuan Wang; Stefano Martellucci; Alicia Van Enoo; Dana Austin; Cohava Gelber; Wendy M Campana
Journal:  FASEB J       Date:  2022-01       Impact factor: 5.834

4.  High-affinity binding of plasminogen-activator inhibitor 1 complexes to LDL receptor-related protein 1 requires lysines 80, 88, and 207.

Authors:  Mary Migliorini; Shih-Hon Li; Anqi Zhou; Cory D Emal; Daniel A Lawrence; Dudley K Strickland
Journal:  J Biol Chem       Date:  2019-12-02       Impact factor: 5.157

5.  Recombinant Expression of the Full-length Ectodomain of LDL Receptor-related Protein 1 (LRP1) Unravels pH-dependent Conformational Changes and the Stoichiometry of Binding with Receptor-associated Protein (RAP).

Authors:  Camilla De Nardis; Philip Lössl; Maartje van den Biggelaar; Pramod K Madoori; Nadia Leloup; Koen Mertens; Albert J R Heck; Piet Gros
Journal:  J Biol Chem       Date:  2016-12-12       Impact factor: 5.157

6.  Engineered Tissue Inhibitor of Metalloproteinases-3 Variants Resistant to Endocytosis Have Prolonged Chondroprotective Activity.

Authors:  Christine M Doherty; Robert Visse; Deendayal Dinakarpandian; Dudley K Strickland; Hideaki Nagase; Linda Troeberg
Journal:  J Biol Chem       Date:  2016-08-31       Impact factor: 5.157

7.  Factor VIII/V C-domain swaps reveal discrete C-domain roles in factor VIII function and intracellular trafficking.

Authors:  Eduard H T M Ebberink; Eveline A M Bouwens; Esther Bloem; Mariëtte Boon-Spijker; Maartje van den Biggelaar; Jan Voorberg; Alexander B Meijer; Koen Mertens
Journal:  Haematologica       Date:  2017-01-05       Impact factor: 9.941

8.  Isolated Variable Domains of an Antibody Can Assemble on Blood Coagulation Factor VIII into a Functional Fv-like Complex.

Authors:  Svetlana A Shestopal; Leonid A Parunov; Philip Olivares; Haarin Chun; Mikhail V Ovanesov; John R Pettersson; Andrey G Sarafanov
Journal:  Int J Mol Sci       Date:  2022-07-23       Impact factor: 6.208

9.  Soluble LRP1 is an independent biomarker of epicardial fat volume in patients with type 1 diabetes mellitus.

Authors:  David de Gonzalo-Calvo; Cristina Colom; David Vilades; Andrea Rivas-Urbina; Abdel-Hakim Moustafa; Montserrat Pérez-Cuellar; Jose Luis Sánchez-Quesada; Antonio Pérez; Vicenta LLorente-Cortes
Journal:  Sci Rep       Date:  2018-01-18       Impact factor: 4.379

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.